Senti Bio receives additional $1M tranche from CIRM grant

Senti Bio (SNTI)sciences reported the receipt of an additional $1M from the California Institute of Regenerative Medicine, CIRM, upon the achievement of clinical study enrollment milestones. As previously announced, the CIRM awarded an $8 million grant to Senti Bio to support the ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer, CAR-NK, investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia. To date, the Company has received a total of $7.4 million of the $8.0 million available under the grant.